William V. Williams
27Patents
14h-index
20Co-inventors
81Inventor score
Filing activity: Jun 21, 1990 → Dec 29, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5593972A | Genetic immunization | Emerging Cross-Sectional Technologies | 259 | Expired |
| US5817637A | Genetic immunization | Emerging Cross-Sectional Technologies | 136 | Expired |
| US5830876A | Genetic immunization | Emerging Cross-Sectional Technologies | 117 | Expired |
| US5981505A | Compositions and methods for delivery of genetic material | Emerging Cross-Sectional Technologies | 80 | Expired |
| US5714316A | Chimeric envelope proteins for viral targeting | Chemistry; Metallurgy | 73 | Expired |
| US5556744A | Methods and compositions for diagnosing and treating certain HIV infected patients | Emerging Cross-Sectional Technologies | 44 | Expired |
| US5837460A | Methods of identifying biologically active receptor-binding peptides | Emerging Cross-Sectional Technologies | 33 | Expired |
| US5637677A | Biologically active compounds and methods of constructing and using the same | Chemistry; Metallurgy | 32 | Expired |
| US10166191B2 | Sustained-release dosage forms of ruxolitinib | Human Necessities | 29 | Active |
| US5219837A | Method of stimulating myelination of cells | Human Necessities | 25 | Expired |
| US5840300A | Methods and compositions comprising single chain recombinant antibodies | Human Necessities | 25 | Expired |
| US5574009A | Method of stimulating myelination of cells | Human Necessities | 19 | Expired |
| US6468982B1 | Genetic immunization | Emerging Cross-Sectional Technologies | 18 | Expired |
| US10874616B2 | Sustained-release dosage forms of ruxolitinib | Human Necessities | 15 | Active |
| US6087486A | Nucleotide sequences encoding vpr receptor protein | Physics | 14 | Expired |
| US6228621A | Plasmids encoding immunogenic proteins and intracellular targeting sequences | Chemistry; Metallurgy | 11 | Expired |
| US11337927B2 | Sustained-release dosage forms of ruxolitinib | Human Necessities | 10 | Active |
| US5338829A | Peptides derived from human immunodeficiency virus-1 GP160 | Chemistry; Metallurgy | 7 | Expired |
| US8304234B2 | Compositions and methods for delivery of genetic material | Emerging Cross-Sectional Technologies | 3 | Active |
| US6248565A | Immunization with plasmid encoding immunogenic proteins and intracellular targeting sequences | Chemistry; Metallurgy | 2 | Expired |
| US7001759B1 | Compositions and methods for delivery of genetic material | Emerging Cross-Sectional Technologies | 1 | Expired |
| US11576865B2 | Sustained-release dosage forms of ruxolitinib | Human Necessities | 0 | Active |
| US11896717B2 | Sustained-release dosage forms of ruxolitinib | Human Necessities | 0 | Active |
| US6372884B1 | Biologically active compounds and methods of constructing and using the same | Chemistry; Metallurgy | 0 | Expired |
| US11576864B2 | Sustained-release dosage forms of ruxolitinib | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.